The Series A round was led by Define Ventures, with participation from Y Combinator and the California Health Care Foundation Innovation Fund. The post Readily Secures $11M for Compliance Intelligence Platform appeared first on MedCity News.

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer The post GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer appeared first on MedCity News.

Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail. The post A Radical Proposal to Preserve Cell and Gene Therapy Innovation appeared first on MedCity News.

A new report on third quarter M&A activity in the healthcare sector found that this quarter’s hospital and health system transactions remained steady, with 2026 potentially set to be a top year for total annual transactions since pre-pandemic times. The post Report: Health System M&A Activity Remains Steady in Third Quarter appeared first on MedCity News.

AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity. The post AdvaMed’s 4 Policy Priorities, According to Its CEO appeared first on MedCity News.

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and a potential dosing advantage over a Takeda Pharmaceutical product recently approved in this indication. The post Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer appeared first on MedCity News.

Phantom GI, a Tel Aviv-based medical startup, is developing the PercStoma device, a minimally invasive alternative to traditional ostomy surgery. The device would target patients with bowel obstructions who might otherwise be considered ineligible for surgery. The post With $5M, Phantom GI Plans to Develop Minimally Invasive Alternative Ostomy Surgery Device appeared first on MedCity News.

Some of the thorniest problems in medicine that AI can improve have nothing to do with diagnosis. They have to do with triage.  The post Diagnosis Is Beside the Point appeared first on MedCity News.

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. The post Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder appeared first on MedCity News.

Allswell’s seed round was led by Rethink Impact, and included participation from Magnify Ventures, Ulu Ventures and Hopelab Ventures, joining existing investors Techstars and Amboy Street Ventures. The post Allswell Raises $7M to Grow LGBTQ+ Behavioral Health Platform appeared first on MedCity News.

This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on. The post The Antibiotics Exist —The System Cannot Deliver Them appeared first on MedCity News.

Health care routinely recommends movement without providing assessment, dosage, progression, and follow-up that turn good advice into usable care. The post Exercise is Prescribed Like Advice When It Should Be Delivered Like Treatment appeared first on MedCity News.

UPMC Enterprises is making a strategic investment in VeloSource with plans to further develop its AI-enabled staffing management platform. The post UPMC Enterprises Invests in VeloSource to Expand AI-Enabled Clinician Staffing Platform appeared first on MedCity News.

Epic will launch a tool in summer 2027 to help patients compare prescription cash prices and insurance costs across pharmacies. The post Why Epic Is Launching a Prescription Price Comparison Tool appeared first on MedCity News.

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. The post City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver appeared first on MedCity News.